The Key Players in Global Retinoblastoma Treatment Market 2015-2019

Monday 10 August 2015, Amsterdam

The report recognizes the following companies as the key players in the Global Retinoblastoma Treatment Market: Baxter, Bristol-Myers Squibb, GlaxoSmithKline, and Spectrum Pharmaceuticals

Other Prominent Vendors in the market are: BioLineRx, Cellceutix, Icon Bioscience, Neotropix, RXi Pharmaceuticals, and Recombio

Commenting on the report, an analyst said: “The primary aim of twinning programs was to develop retinoblastoma treatment units. It involved collaboration among governments, private sector institutions, and nongovernmental organizations. These initiatives provide better healthcare facilities in terms of primary care, knowledge of diseases, and more effective decision-making for disease treatment.”

According to the report, awareness campaigns aimed at parents and healthcare professionals lead to early disease diagnosis and improved survival rates. In Honduras, an awareness campaign for the timely recognition of retinoblastoma yielded positive results in terms of disease diagnosis and treatment.

Further, the report states that the social stigma associated with cancer, fear of removal of the eye, and financial burden are the primary reasons for treatment refusal. Tumor progression to other parts of the body and low survival rate further complicates the situation.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Global Retinoblastoma Treatment Market 2015-2019

Global Retinoblastoma Treatment Market 2015-2019

Publish date : August 2015
Report code : ASDR-212492
Pages : 62

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News